FDA Office of Prescription Drug Promotion (OPDP) · United States
FDA OPDP Off-Label Promotion Prohibition
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance. Apply to consumer and HCP-directed prescription drug promotion and scientific communications in any US channel.
general_audience, general_adults_18plus, customers, patients, health_professionals · Prescription Drug · pharma
Where does this rule apply?
United States
Which marketing channels are covered?
all_channels
When does this rule take effect?
2018-06-04
What does this rule require?
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
How can marketing teams comply?
Apply to consumer and HCP-directed prescription drug promotion and scientific communications in any US channel.
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
Who does this rule apply to?
general_audience, general_adults_18plus, customers, patients, health_professionals · Prescription Drug · pharma
Alabama's medical cannabis program (Alabama Medical Cannabis Commission (AMCC)) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Arkansas's medical cannabis program (Arkansas Medical Marijuana Commission) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Hawaii's medical cannabis program (Hawaii Department of Health — Medical Cannabis Registry) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Iowa's medical cannabis program (Iowa Department of Health and Human Services (Iowa HHS), Office of Medical Cannabidiol) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Kentucky's medical cannabis program (Kentucky Cabinet for Health and Family Services — Office of Medical Cannabis) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Louisiana's medical cannabis program (Louisiana Department of Health — Medical Marijuana Program) bars marketing that appeals to minors, promotes non-medical use or reaches people without a patient registration, or makes cure or safety claims.
Request a free compliance scan of your homepage and book a time with Warrant.